Jakob Knudsen
Chief Executive Officer at VIROGATES A/S
Net worth: 118 355 $ as of 2024-03-30
Profile
Jakob Knudsen is currently the Chief Executive Officer at ViroGates A, an Independent Director at ExpreS2ion Biotechnologies ApS, the Director of Mr. Knudsen Enkeltmandsvirksomhed, an Independent Director at Expres2ion Biotech Holding AB, a Director at Ingeniørsystem A, and a Non-Executive Director at P.V.
Fonden.
Previously, he held the position of Head-Business Development at ALK-Abello A from 1999 to 2008 and Chief Financial & Commercial Officer at Egalet Ltd.
from 2008 to 2011.
He holds an MBA from Imperial College London and a graduate degree from the University of Copenhagen.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
VIROGATES A/S
1.95% | 2023-12-30 | 125,514 ( 1.95% ) | 118 355 $ | 2024-03-30 |
Jakob Knudsen active positions
| Companies | Position | Start |
|---|---|---|
| EXPRES2ION BIOTECH HOLDING AB | Director/Board Member | 2017-03-31 |
| VIROGATES A/S | Chief Executive Officer | 2011-03-31 |
ExpreS2ion Biotechnologies ApS
 ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Director/Board Member | - |
| P.V. Fonden | Director/Board Member | - |
| Ingeniørsystem A/S | Director/Board Member | - |
| Jakob Knudsen Enkeltmandsvirksomhed | Director/Board Member | - |
Former positions of Jakob Knudsen
| Companies | Position | End |
|---|---|---|
Egalet Ltd.
 Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Director of Finance/CFO | 2011-03-31 |
| ALK-ABELLÓ A/S | Corporate Officer/Principal | 2008-01-31 |
Training of Jakob Knudsen
| Imperial College London | Masters Business Admin |
| University of Copenhagen | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ALK-ABELLÓ A/S | Health Technology |
| VIROGATES A/S | Health Technology |
| EXPRES2ION BIOTECH HOLDING AB | Health Technology |
| Private companies | 5 |
|---|---|
Egalet Ltd.
Egalet Ltd. Pharmaceuticals: MajorHealth Technology Egalet Ltd. engages in manufacturing of basic pharmaceutical products. It focuses on the commercialization and development of abuse resistant formulations of opioids and other pain care drugs. The company was founded on July 15, 2010 and is headquartered in London, the United Kingdom. | Health Technology |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | Health Technology |
| Ingeniørsystem A/S | |
| P.V. Fonden | |
| Jakob Knudsen Enkeltmandsvirksomhed |
- Stock Market
- Insiders
- Jakob Knudsen
